BSD Medical Announces Purchase of BSD-500 Hyperthermia System by Loyola University Medical Center

  BSD Medical Announces Purchase of BSD-500 Hyperthermia System by Loyola
  University Medical Center

Business Wire

SALT LAKE CITY -- December 17, 2013

BSD Medical Corporation (NASDAQ:BSDM) (the “Company” or “BSD”) announced today
that Loyola University Medical Center (LUMC) in Maywood, Illinois has
purchased a BSD-500 Hyperthermia System (BSD-500). Loyola University Medical
Center (LUMC) is the core of the Loyola University Health System and one of
the nation’s leading academic medical centers. In the U.S. News 2013-14
hospital rankings, Loyola's Cancer program was rated among the top 25 percent
of hospitals in cancer treatment. LUMC is nationally recognized for providing
technologically advanced treatments and for promoting patient safety. The
purchase of the BSD-500 by this prestigious medical center is further evidence
of the growing use of hyperthermia therapy in the United States and will
increase the number of patients who will have access to innovative
hyperthermia treatment.

“Hyperthermia has been shown to be an effective adjuvant therapy for several
types of cancers. It offers patients additional therapy options in their fight
against cancer,” stated Dr. William Small Jr., Professor and Department
Chairperson, Radiation Oncology, at LUMC. “I am excited to be able to offer
this treatment modality here at Loyola University Medical Center and to
continue to participate in research on the efficacy of this treatment option
in additional types of cancers.”

About Loyola University Medical Center Radiation Oncology Department

The Radiation Oncology department at LUMC offers a full line of sophisticated
radiation oncology treatment modalities, including unfractionated and
fractionated stereotactic radiosurgery, external beam, rapid arc, image-guided
radiotherapy, intensity-modulated radiation therapy, high-dose-rate and
low-dose-rate brachytherapy, total body irradiation, electron beam, prostate
seed implant, and intra-operative radiotherapy (IORT). Consistent with its
education and research mission, the department is actively engaged in ongoing
research, including innovative investigator initiated and cooperative group
trials, translational, physics and basic science research.

The department, working in tandem with the other Cancer Service Line
specialists at Loyola, provides an integrated approach to providing both
treatment and support services to patients.

About the BSD-500 Hyperthermia System

The BSD-500 Hyperthermia System is used to deliver therapeutic heating
(hyperthermia) using either non-invasive (external) hyperthermia, which is
delivered using antennas placed over the tumor, or interstitial hyperthermia,
which is delivered using antennas that are inserted into the tumor, or a
combination of both. The BSD-500 has received U.S. Food and Drug
Administration (FDA) pre-market approval (PMA) for the use of hyperthermia in
conjunction with radiation therapy to treat certain tumors.

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems
to treat cancer and benign diseases using heat therapy, which is delivered
using focused radiofrequency (RF) and microwave energy. BSD’s product lines
include both hyperthermia and ablation treatment systems. BSD’s MicroThermX
microwave ablation system has been developed as a stand-alone therapy to
employ precision-guided microwave energy to ablate (destroy) soft tissue. The
Company has developed extensive intellectual property, multiple products in
the market and established distribution in the United States, Europe and Asia.
Certain of the Company’s products have received regulatory approvals and
clearances in the United States, Europe and China. For further information
visit BSD Medical's website at www.BSDMedical.com.

This press release may be deemed to contain forward-looking statements, which
are subject to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Readers are cautioned that these forward-looking
statements are only predictions and may differ materially from actual future
events or results due to a variety of factors, including, among other things,
the demand for the Company’s products, the ability of the Company to produce
the products to meet the demand, global economic conditions and uncertainties
in the geopolitical environment and other risk factors set forth in the
Company’s most recent reports on Form 10-K and Form 10-Q. Any forward-looking
statements in this release are based on limited information currently
available to the Company, which is subject to change, and the Company will not
necessarily update the information.

Contact:

BSD Medical Corporation
William (Bill) S. Barth, 801-972-5555
fax: 801-972-5930
investor@bsdmc.com
 
Press spacebar to pause and continue. Press esc to stop.